"Medivation price target raised to $89 from $70 at Citigroup
Citigroup raised its price target for Medivation shares to $89 on expectations Xtandi will beat estimates. Citi expects peak sales of $6.5B in 2026 and keeps a Buy rating on the stock."
All articles have J&J both getting share. I donr see that at all. Why would they prescribe J&J as they use prednisone and the data is not as good. Thats why Citi and GS has it dead on. Xtandi will keep blowing away the numbers. Buyout and breast cancer is icing on the cake!